Dermatology

Phase 2 LANTIC trial data show corabotase maintained glabellar line improvement in 60.8% of patients at week 24 versus 36.7% for Dysport.

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

Patients with atopic dermatitis and prurigo nodules (AD-PN) saw notable itch reduction in 12 weeks after initiating upadacitinib.

In this May episode of The Medical Sisterhood podcast, the show features guest Lisa Swanson, MD, discussing the emotional realities of pediatric dermatology.

Treatment-associated phenotype switching between psoriasis and atopic dermatitis was noted to be reproducible and bidirectional in real-world clinical settings.

Investigators released long-term data on long-term bimekizumab use in psoriasis suggest, demonstrating sustained efficacy through 4 years.

Investigators used the Global Burden of Disease (GBD) 2023 database to summarize skin cancers’ epidemiology, patterns, and projections to 2050.

This segment of a recent Skin of Color Savvy podcast highlights the experts' views on education related to colorism and skin pigment-related concerns.

This large real-world analysis of patients with vitiligo suggests many individuals remain untreated after diagnosis.

Seemal R. Desai, MD, and Pearl E. Grimes, MD, discuss the complexities of colorism and its impact on pigmentary disorders.

New OX40 biologics aim for longer atopic dermatitis control, but Kaposi's sarcoma concerns split experts as amlitelimab advances and rocatinlimab halts.

Findings suggest potential value in complete blood count (CBC)-derived parameters for assessments of hidradenitis suppurativa (HS) disease activity and severity.

In this segment of his interview, Chovatiya speaks about how new consensus definitions on atopic dermatitis disease activity could impact clinical trials.

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

Noreen Galaria, MD, highlighted the evolving role of internal photoprotection alongside practical, habit-based strategies to support physician wellness and reduce burnout.

This segment of the latest episode of the Skin of Color Savvy podcast highlights key challenges faced by Galaria in her dermatology practice.

In the ongoing JADE EXTEND trial, long-term treatment with abrocitinib led to sustained skin clearance and other improvements through 112 weeks.

In this new Skin of Color Savvy podcast, Noreen Galeria, MD, discusses topics such as patient, misinformation, her career, and research on natural remedies.

In this segment from the April episode of The Medical Sisterhood podcast, the speakers discussed simple ways for physicians to get involved in community service without feeling overwhelmed.

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

Elizabeth Kiracofe, MD, speaks in this segment of her recent The Medical Sisterhood podcast about her career and other community initiatives.

In this Q&A interview, Hordinsky was asked about recent 1-year data on clascoterone solution 5% in androgenetic alopecia (AGA).

Are IL-23 inhibitors, rather than IL-17 inhibitors, the preferred biologic for psoriasis patients at risk of developing psoriatic arthritis?

In this April episode, the discussion highlights how intentional choices and practice ownership can help physicians align professional with personal success.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.